HomeMy WebLinkAboutOriginal NEXUS ContractUniversity of Washington
Research Subaward Agreement
Prime Recipient:
UNIVERSITY OF WASHINGTON (UW)
UW Principal Investigator (PI):
Sara Glick
Award No: FAIN:
5 NU65PS923685-02-00 NU65PS923685
Federal Award Date:
7/27/2020
Subrecipient:
County of Kittitas
Subrecipient Principal Investigator (PI):
Chelsey Loeffers
Awarding Agency:
Centers for Disease Control and Prevention
CFDA No and Title:
93.488 - National Harm Reduction Technical Assistance,
Monitoring and Evaluation, and
Communications Funding Opportunity
Project Title:
Subaward No.
National Harm Reduction Technical Assistance and
UWSC12491
Syringe Services Program Monitoring and Evaluation
Subaward Period of Performance: I
Amount Funded This Action:
Start: 9/30/2020 End: 9/29/2021
$95,936
Estimated Project Period (if incrementally funded)
Incrementally Estimated Total:
Start: 9/30/2020 End: 9/29/2021
$95,936
TERMS AND CONDITIONS
BPO #
55135
Subject to FFATA
® Yes ❑ No
Is this Award R&D?
❑ Yes ❑X No
The University of Washington, an institution of higher education and an agency of the State of Washington having its
principal campus located in Seattle, Washington, hereby awards a cost reimbursable subaward, as described above, to
the above -identified subrecipient. NOW, THEREFORE, in consideration of the foregoing and the terms and conditions
contained in this agreement ("Subaward Agreement"), UW and Subrecipient do hereby agree as follows:
1) STATEMENT OF WORK, BUDGET AND PRIME AWARD. The statement of work ("Statement of Work") and budget
("Budget") for this Subaward Agreement are hereby incorporated as Attachment 5. This Subaward Agreement is subject
to the terms and conditions of the Prime Award identified above and included herein as Attachment 1.
2) INVOICING AND PAYMENT. UW shall reimburse Subrecipient not more often than monthly but not less than quarterly
for actual allowable costs incurred for the performance of the Statement of Work, and in accordance with the Budget
incorporated as Attachment 5, provided that:
a) The total of such costs does not exceed the estimated cost as set forth in Attachment 5 herein;
b) Such costs were allowable by terms of this Subaward Agreement;
c) Such costs are incurred in accordance with Subrecipient's established policies and procedures; and
d) Subrecipient adheres to the following cost principles, as applicable: (i) 2 C.F.R. § 200, Uniform Administrative
Requirements, Cost Principles, and Audit Requirements for Federal Awards, (ii) for hospitals, 45 CFR 74, Appendix
E; or (iii) Subrecipient's established policies and procedures.
All invoices shall be submitted using Subrecipient's standard invoice, but at a minimum shall include current and
cumulative costs (including cost sharing) listed by budget category, subaward number, purchase order number, and
certification as to truth and accuracy of invoice. A final statement of cumulative costs incurred (including cost share) listed
by budget category and marked "FINAL" must be submitted NOT LATER THAN sixty (60) days after subaward end date.
No invoices submitted after sixty (60) days from the end of the subaward shall be paid. The final statement of costs shall
constitute Subrecipient's final financial report.
Subrecipients that are registered in the Ariba eCommerce platform and are fully enabled to do business with UW via the
Ariba Network (UW's eProcurement System) shall submit invoices via the Ariba network. Ariba invoice creation
instructions can be found at: https://f2.washington.edu/fm/pslAribaBlanketPurchaseOrders/b2oreceivincisuppliers.
Subrecipients not yet fully enabled shall submit invoices via email to uwboo@uw.edu. Invoices that do not originate from
the Ariba Network or the UW email uwb o uw.edu, as appropriate, will not be paid.
UW Research Subaward Agreement — Cost Reimbursement DOMESTIC Page 1 of 5
Version JAN2019
Questions concerning invoice receipt or payments should be directed to the appropriate party's Financial Contact as
indicated in Attachment 3A.
All payments shall be considered provisional and subject to adjustment within the total estimated cost in the event such
adjustment is necessary as a result of an adverse audit finding against the Subrecipient. UW reserves the right to reject
an invoice that is not consistent with the terms of this Subaward Agreement.
3) NOTIFICATION. Any request for negotiation of changes in the terms, conditions, or amounts in this Subaward
agreement and any matters requiring UW's prior approval shall be directed to the appropriate party's Administrative
Contact in Attachments 3A and 313. Any such changes made to this Subaward Agreement require the written approval of
each party's Authorized Official as shown in Attachments 3A and 3B.
4) REPORTS. Reporting requirements shall be fulfilled in accordance with Attachment 4.
5) PUBLICATIONS. Subrecipient agrees that all publications that result from work under this Subaward Agreement shall
acknowledge that the project was supported by Awarding Agency and reference the Award No. above.
6) INVENTIONS. Consistent with U.S. Public Law 96-517, as amended by U S. Public Law 98-620, title to any invention
made or conceived solely by Subrecipient in performing work under this Subaward Agreement shall vest in the
Subrecipient ("Subrecipient Invention"). Inventions made or conceived solely by UW shall be owned by UW. Inventions
made or conceived jointly by UW and Subrecipient shall be owned by UW and Subrecipient in accordance with U.S.
patent and other applicable U.S. laws. Subrecipient shall promptly notify UW PI (as shown in Attachment 3A) in writing of
any such Subrecipient inventions. Subrecipient hereby grants to UW a royalty -free, non-exclusive license for internal
research and educational purposes to any such Subrecipient invention.
7) TERMINATION. Either party may terminate this Subaward Agreement upon thirty (30) days' written notice to the other
party's Administrative and Authorized Contact as set forth in Attachments 3A and 3B. Upon receipt of such notice of
termination, Subrecipient shall use reasonable efforts to limit or terminate any outstanding financial commitments related
to the work to be performed under this Subaward Agreement. UW shall reimburse Subrecipient for all reasonable costs
incurred by Subrecipient under this Subaward Agreement through the date of termination which are allowable in
accordance with all applicable laws, regulations, terms and conditions, including without limitation, all reasonable and
necessary non -cancellable financial obligations incurred by Subrecipient to carry out its work under this Subaward
Agreement.
8) USE OF NAME. Neither party shall use the name of the other party, or the name of any faculty member, employee, or
student of the other party, in connection with any product, service, promotion, news release, or other publicity without the
prior written permission of the other party and in the case of an individual, the prior written permission of that individual.
The parties agree that each party may use factual information regarding the existence and purpose of the relationship that
is the subject of this Agreement for legitimate business purposes, to satisfy any reporting and funding obligations, or as
required by applicable law or regulation without written permission from the other party. In any such statement, the
relationship of the parties shall be accurately and appropriately described.
9) NOTICE OF DISPUTE, NEGOTIATION AND MEDIATION. Prior to commencing any legal action, the parties will
attempt in good faith to resolve through negotiation any dispute, claim or controversy arising out of or relating to this
Subaward Agreement. Either party may initiate such negotiations by providing written notice to the other party specifying
that this provision of this Subaward Agreement is being utilized and setting forth the subject of the dispute and the relief
requested. The party receiving such notice will respond in writing within ten (10) business days with a statement of its
position on and recommended solution to the dispute. If the dispute is not resolved by this exchange of correspondence,
then representatives of each party with full settlement authority shall meet at a mutually agreeable time and place within
ten (10) business days of the date of the initial notice in order to exchange relevant information and perspectives, and to
attempt in good faith to resolve the dispute. If the dispute is not resolved by these negotiations, the matter will be
submitted to a mutually agreeable and recognized nonbinding mediation service prior to initiating legal action. The costs
of the mediation service shall be shared equally by the parties.
10) DEBARMENT. Subrecipient certifies that it is not excluded, debarred, suspended or otherwise ineligible to participate
in federal programs. In connection with the performance of their respective obligations under this Agreement, the parties
shall not knowingly employ or contract with, whether or not for compensation, any individual, or entity currently listed by a
federal agency as excluded, debarred, suspended or otherwise ineligible to participate in federal programs.
11) NONDISCRIMINATION. Subrecipient shall not engage in any unlawful discrimination nor will it discriminate against
any person because of race, color, religion, national origin, age, handicap, status as a Vietnam era or disabled veteran,
UW Research Subaward Agreement — Cost Reimbursement DOMESTIC Page 2 of 5
Version JAN2019
sex, or sexual orientation with respect to their employment, personnel, or patient care policies and practices as those
matters may relate to the performance of the parties' respective obligations under this Subaward Agreement.
To the extent required by law or regulation, the Subrecipient and their contractors, subcontractors, and
subrecipients shall abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These
regulations prohibit discrimination against qualified individuals based on their status as protected veterans or
individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion,
sex, sexual orientation, gender identity or national origin. Moreover, these regulations require that covered prime
contractors, subcontractors, and subrecipients take affirmative action to employ and advance in employment
individuals without regard to race, color, religion, sex, sexual orientation, gender identity, national origin,
protected veteran status or disability.
12) ANTI-TERRORIST COMPLIANCE. Subrecipient hereby certifies that all funds, including sub -awards by it to lower -tier
subrecipients, will be used in compliance with all applicable United States anti-terrorist financing and asset control laws,
regulations, rules and executive orders.
13) CONFORMATION TO APPLICABLE LAWS AND PROFESSIONAL STANDARDS. Subrecipient certifies that
Subrecipient and those persons participating in the conduct of the Statement of Work under this Subaward Agreement will
conform to and obey all applicable laws, ordinances, rules, regulations, requirements and orders of all municipal, county,
state or federal authorities or agencies and all professional standards applicable to the conduct of the research under this
Subaward Agreement.
14) QUALIFICATIONS, LICENSES, PERMITS. Upon request by UW, Subrecipient shall provide UW evidence of any
licenses, permits, certifications or accreditations required to conduct the Statement of Work under this Subaward
Agreement.
15) LEGAL COMPLIANCE. The parties intend this Subaward Agreement to comply with all applicable laws, regulations
and requirements. The parties further agree this Subaward Agreement shall be applied and interpreted in a manner
consistent with full compliance with all such laws, regulations and requirements. If at any time either party has reasonable
grounds to believe that this Subaward Agreement, or the work to be performed under it, may not conform to the then -
current requirements or interpretations relevant to such matters, both parties agree that they will promptly negotiate in
good faith for the purposes of bringing this Subaward Agreement into full compliance with such then -current requirements
and interpretations.
16) EXPORT CONTROLS. It is understood that the parties are subject to United States laws and regulations controlling
the export of technical data and information, computer software, laboratory prototypes and other commodities, and that its
obligations hereunder are contingent on compliance with applicable U.S. export laws and regulations (including without
limitation the Arms Export Control Act, as amended, and the Export Administration Act of 1979) ("Export -Controlled
Materials"). The transfer of any such technology and items and the entering into and provision of such transactions and
services that are subject to restrictions may require a license or authorization from the cognizant agency of the United
States Government, and/or may require written assurances by the receiving party that it shall not re-export such
technology and items to certain foreign destinations and/or to certain recipients without prior approval of the cognizant
government agency, and/or may require that the involved individuals and entities will comply with conditions on
Transactions and Services. While each party agrees to cooperate in securing any license which the cognizant agency
deems necessary in connection with this Agreement, neither party can guarantee or make assurances that such licenses
can or will be granted Each party agrees that it will not provide or make accessible to the other party any Export -
Controlled Materials without first notifying the receiving party in writing of the existence and nature of the Export -
Controlled Materials and obtaining the prior written agreement of the receiving party, through a duly -authorized
representative, for the receiving party to receive such Export -Controlled Materials. All Export -Controlled Materials shall be
conspicuously labeled "Export Controlled" together with any applicable Export Control Classification Number.
17) AUDIT AND ACCESS TO RECORDS. If Subaward is subject to 2 C.F.R §200, Subrecipient certifies by signing this
Subaward Agreement that they comply with the Uniform Guidance, will provide notice of any adverse findings which
impact this subaward as required by parts 200.501- 200.521, and will provide access to records as required by parts
200.336, 200.337, and 200.201 as applicable.
In the event Subaward or Subrecipient is not subject to 2 C.F.R. § 200, UW may require Subrecipient to provide UW with
Subrecipient's most recent audit report or statement on compliance and on internal controls prepared by an independent
accountant or public auditing firms. In certain cases, Subrecipient may be required to arrange for a limited scope audit
verifying Subrecipient's compliance with the requirements for this Subaward Agreement.
UW Research Subaward Agreement — Cost Reimbursement DOMESTIC Page 3 of 5
Version JAN2019
In any event, the Subrecipient shall maintain acceptable financial management systems during the term of this Subaward
Agreement. Such systems shall include:
a) accurate, current and complete disclosure of the financial activity of this Subaward Agreement;
b) records that identify the source and application of the UW's funds paid;
c) effective control over and accountability for all funds, property and other assets;
d) comparison of actual outlays with budgeted amounts;
e) consistency with the applicable federal administrative requirements and cost principles, if applicable; and
f) accounting records supported by source documentation.
Subrecipient agrees that the UW shall, until the expiration of three (3) years after final payment under this Subaward
Agreement, have access to and right to examine all aspects of the Statement of Work undertaken under this Subaward
Agreement, and all books, records, and documents of any kind pertaining to the Subaward Agreement, including any
directly pertinent records involving transactions related to this Subaward Agreement for the purpose of making audits,
examinations, excerpts and transcriptions, if applicable. It is understood that, unless agreed to in writing by Subrecipient,
such examination shall be made during Subrecipient's regularly established business hours. Records related to any audit
initiated prior to the expiration of the three-year period shall be retained until the audit findings involving the records have
been resolved.
Failure to comply with the terms of this Audit and Access to Records section may lead to termination of this Subaward
Agreement
18) NO PARTNERSHIP/JOINT VENTURE. The relationship of the parties under this Subaward Agreement is that of
independent contractors and they are not agents, employees, partners or joint ventures of one another. No party has the
authority to bind any other party in contract or to incur any debts or obligations on behalf of any other party, and no party
(including the UW PI and Subrecipient PI) shall take any action that attempts or purports to bind any other party in
contract or to incur any debts or obligations on behalf of any other party, without the affected party's prior written approval
19) ENTIRE AGREEMENT AND ORDER OF PRECEDENCE. This Subaward Agreement constitutes the entire
agreement between the parties, and supersedes all prior oral or written agreements, commitments, or understandings
concerning the matters provided for herein. This Subaward Agreement consists of the following documents which are
hereby incorporated by reference:
a) UW Research Subaward Agreement
b) Attachment 1: Prime Award Terms and Conditions
c) Attachment 2: Special Terms & Conditions
d) Attachment 3A: Prime Recipient Contacts
e) Attachment 3B: Subrecipient Contacts
f) Attachment 4: Reporting Requirements
g) Attachment 5: Statement of Work and Budget
In the event of any conflict between the terms and conditions set forth in this Subaward Agreement and the Attachments,
the parties agree that the terms and conditions included in Attachment 1: "Prime Award Terms and Conditions" shall take
precedence.
20) AMENDMENT. This Subaward Agreement may only be modified by a subsequent written agreement executed by the
duly -authorized representatives of the parties. The UW PI and Subrecipient PI shall have no authority to amend this
Subaward Agreement or to waive any right or obligation arising hereunder.
21) SEVERABILITY. If any provision of this Subaward Agreement or of any other agreement, document or writing
pursuant to or in connection with this Subaward Agreement, shall be wholly or partially invalid or unenforceable under
applicable law, said provision will be ineffective to that extent only, without in any way affecting the remaining parts or
provision of said agreement, provided that the remaining provisions continue to effect the purposes of this Subaward
Agreement.
22) WAIVER. Neither the waiver by any of the parties hereto of a breach of or a default under any of the provisions of this
Subaward Agreement, nor the failure of either of the parties, on one or more occasions, to enforce any of the provisions of
this Subaward Agreement or to exercise any right or privilege hereunder will thereafter be construed as a waiver of any
subsequent breach or default of a similar nature, or as a waiver of any such provisions, rights or privileges hereunder.
23) FORCE MAJEURE. Nonperformance by a party, other than payment of any amounts due hereunder, shall not
operate as a default under or breach of the terms of this Agreement to the extent and for so long any such
UW Research Subaward Agreement — Cost Reimbursement DOMESTIC Page 4 of 5
Version JAN2019
nonperformance is due to: strikes or other labor disputes; prevention or prohibition by law; the loss or injury to products in
transit; an Act of God; or war or other cause beyond the control of such party.
24) ASSIGNMENT AND SUCCESSORS IN INTEREST. Except as otherwise provided herein, no party may assign,
subcontract, or delegate any right or obligation under this Subaward Agreement, in whole or in part, without the express
prior written consent of the other party. This Subaward Agreement shall inure to the benefit of and be binding upon each
party's successors and assigns.
25) COUNTERPARTS. This Subaward Agreement may be executed in any number of counterparts or, if mutually
agreeable to the undersigned authorized signatories for the parties, through the exchange by facsimile or other electronic
means of duly -signed duplicates hereof, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
IN WITNESS WHEREOF, the duly -authorized representatives of the parties have entered into this Subaward Agreement
as of the date of the last signature of UW and Subrecipient below.
University of Washington
By:
Print Name: Josy S. Combs
Subaward Administrator
Date: 4/27/2021
UW Research Subaward Agreement — Cost Reimbursement DOMESTIC
Version JAN2019
County of Kittitas_
By:
Print Name: -ilh ► v' ` zanq 1,
Title:
Date:.
T '
Page 5 of 5
Attachment 1
UW Research Subaward Agreement
Prime Award Terms and Conditions
The Prime Award Terms and Conditions contained in this Attachment are modified to the extent where
applicable as follows:
• "Award" shall mean "Subaward";
• "Recipient" shall mean "Subrecipient";
■ "CDC' shall mean "University of Washington"
This Agreement is subject to the following terms and conditions:
Notice of Funding Opportunity (NOFO): PS19-1909
Award Number: NU65PS923685-02
Award Type: Cooperative Agreement
Applicable Regulations: 45 Code of Federal Regulations (CFR) Part 75, Uniform Administrative Requirements,
Cost Principles, and Audit Requirements for HHS Awards
AWARD INFORMATION
Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions
for Non -research awards at blips://www.cdc.gov/grants/fadorairegiifationspoiicies/index.iitm1, the Centers for
Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number
PS19-1909, entitled National Harm Reduction Technical Assistance and Syringe Services Program (SSP)
Monitoring and Evaluation, and application dated June 24, 2019, as may be amended, which are hereby made a
part of this Non -research award, hereinafter referred to as the Notice of Award (NoA).
Financial Assistance Mechanism: Cooperative Agreement
Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic
involvement after the award is made. Substantial involvement is in addition to all post -award monitoring,
technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.
CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients
agree to the responsibilities therein, as detailed in the NOFO.
In a cooperative agreement, CDC staff are substantially involved in the program activities, above and beyond
routine grant monitoring. CDC activities for this program are as follows:
1. Foster communication, coordination and collaboration between awardees working under the
components and demonstration projects.
2. Work with recipients to identify and address challenges that may impede the success of the project.
Recipients must work with the assigned CDC project officer, and other subject matter
3. Provide access to technical guidance and training that will strengthen awardee capacity relevant to
implementation of all required activities of the program.
4. Provide software and/or programming support to collect data from SSPs, SSP clients, and drug -using peers
of SSP clients
5. Provide guidance to awardees on data collection, use, and submission for monitoring and
evaluation activities.
6. Facilitate coordination, collaboration, and where feasible, integration of technical assistance services
among CDC -funded programs (i.e., health departments, CBOs, local and state planning groups, CPN
members); other federal agencies and their recipients; and other partners working with persons with opioid
use disorder and persons who inject drugs.
7. Provide technical guidance to recipients to improve the quality and effectiveness of work plans, evaluation
strategies, products and services, and collaborative activities with other organizations.
8. Collaborate in assessing measurable progress toward meeting program outcomes and in
Page 1 of 4
establishing measurement and accountability systems for documenting outcomes, such as increased
performance improvements and best or promising practices.
9. Collaborate on components to ensure the provision of appropriate and effective technical
assistance services.
10. Collaborate to compile and publish accomplishments, best practices, and lessons learned during the project
period (e.g., through conferences, guidance, material development, webinars, data sharing publications,
other social media, participation in meetings, committees, conference calls and working groups related to
the cooperative agreement and its projects
Program Income: Any program income generated under this grant or cooperative agreement will be used in
accordance with the Addition alternative.
Addition alternative: Under this alternative, program income is added to the funds committed to the project/program
and is used to further eligible project/program objectives.
Note: The disposition of program income must have written prior approval from the GMO.
FUNDING RESTRICTIONS AND LIMITATIONS
Notice of Funding Opportunity (NOFO) Restrictions:
Restrictions that must be considered while planning the programs and writing the budget are:
•Recipients may not use funds for research.
@Recipients may not use funds for clinical care except as allowed by law.
•Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and
services.
*Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be
clearly identified in the budget.
■Reimbursement of pre -award costs generally is not allowed, unless the CDC provides written approval
to the recipient.
e0ther than for normal and recognized executive -legislative relationships, no funds may be used for:
o publicity or propaganda purposes, for the preparation, distribution, or use of any material designed
to support or defeat the enactment of legislation before any legislative body
o the salary or expenses of any cooperative agreement or contract recipient, or agent acting for such
recipient, related to any activity designed to influence the enactment of legislation, appropriations,
regulation, administrative action, or Executive order proposed or pending before any legislative body.
a See Additional Requirement [AR) 12 hgW/Iwww.cdc.ov/grants/add it ion aIrequiremenWindex.htmWar 12)
for detailed guidance on this prohibition and additional_ guidance_ on lobbying ror CDC recipients
(littp://www.cdc.,eov/gran(sfdocuments/Anti- Lobbying_Restrictions_ for _ CDC _Grantees July 2012.pdf).
a The direct and primary recipient in a cooperative agreement program must perform a substantial role in
-carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who
is ineli ible_
a In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental
organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award,
either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from
performing abortions as a method of family planning or engaging in any activity that promotes abortion as a
method of family planning, or to provide financial support to any other foreign non-governmental organization that
conducts such activities. See Additional Requirement (AR) 35 for applicability
(https://www.cdc.gov/grants/additiona[requirements/ar-35.htm1).
Per the Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019
(P.L. 115-245), funds may not be used to purchase syringes or other equipment use solely in the drug injection
process. Any SSP receiving technical assistance or engaged in any projects under this NOFO must be located in a
jurisdiction that has a Determination of Need concurrence from CDC (see ht1ps:1/www.cdc.govlliiylrisklssps-
jurisdictions.html) See HHS guidance on use of federal funds for syringe services programs at
Page 2 of 4
httns://www.cdc.pov/hiv/i)df/risk/hhs-ssD-P-uidance.i3df.
REPORTING REQUIREMENTS
Performance information collection initiated under this cooperative agreement has been approved by the Office
of Management and Budget under OMB Number 0920-1132, "Performance Progress and Monitoring Report",
Expiration Date 8/31/2019.
Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent
with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a
copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law
involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must
disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all
information related to violations of federal criminal law involving fraud, bribery, or gratuity violations
potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at
the following addresses:
CDC, Office of Grants Services
Rhonda Colbert, Grants Management Specialist Centers for Disease Control and Prevention Infectious Disease
Services Branch
2939 Flowers Road, MS TV2
Atlanta, GA 30341-4146
Email: hvxl@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)
U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue,
SW Cohen Building, Room
5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: Mandata�GranteeDisclastiresQoig.hhs.gav
Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.
Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for
noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).
CDC is required to report any termination of a federal award prior to the end of the period of performance due to
material failure to comply with the terms and conditions of this award in the OMB -designated integrity and
performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the
recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms
and conditions of the federal award. (45 CFR 75.373(b))
PROGRAM OR FUNDING GENERAL REQUIREMENTS
Prior Approval: All requests which require prior approval, must be submitted on official organization
letterhead, bear the signature (or electronic authorization) of the authorized organization representative
and be addressed to the Grant Management Specialist. Prior approvals are submitted in Grant Solutions
as an amendment. The recipient must submit these requests no later than June 1, 2020. Additionally, any
requests involving funding issues must include an itemized budget, SF424A, and a narrative justification
of the request.
Page 3 of 4
The following types of requests are examples of actions that require prior approval, unless an expanded
authority, or conversely a high risk condition, is explicitly indicated in the NOA.
• Lift funding restriction
• Significant redirection of funds (i.e. cumulative changes of 25% of total award)
• Change in scope
• Implement a new activity or enter into a sub -award that is not specified in the approved budget
• Apply for supplemental funds
• Change in key personnel
• Extensions to period of performance
Templates for prior approval requests can be found at:
http:l/www_cdc.govlgranWal readyliavegrant/priorapi)rovalreequests.html.
Additional information on the electronic grants administration system CDC non -research awards utilize,
Grants Solutions, can be found at: litt s://w►vw.cdc. ovl rants/ raiitsolutions/index.html.
Key Personnel: In accordance with 45 CFR Part 75.308, CDC recipients must obtain prior approval from CDC
for (1) change in the project director/principal investigator, business official, authorized organizational
representative or other key persons specified in the NOFO, application or award document; and (2) the
disengagement from the project for more than three months, or a 25 percent reduction in time devoted to the
project, by the approved project director or principal investigator.
Page 4 of 4
Attachment 2
UW Research Subaward Agreement
Special Terms and Conditions
1) Subrecipient Insurance and Proof of Coverage. Subrecipient agrees to maintain during the term of this
Agreement comprehensive general liability and professional insurance coverage with limits of not less than $1
million per occurrence and $3 million annual aggregate (or an equivalent program of self-insurance satisfactory to
UW). Upon UW's request, Subrecipient will provide UW proof of insurance or loss coverage required under the
terms of this Agreement. In addition, Subrecipient agrees to notify UW in writing in the event of a material
modification or change in such coverage.
2) Governing Law, Jurisdiction and Venue. This Subaward shall be governed by and enforced according to the
laws of the State of Washington and the United States, without giving effect to its or any other jurisdiction's choice
of law provisions. The Superior Court of Washington for King County shall have exclusive jurisdiction and venue
of all disputes arising under this Agreement, except that in any case where the courts of the United States shall
have exclusive jurisdiction over the subject matter of the dispute, the United States District Court for the Western
District of Washington, Seattle division, shall have exclusive jurisdiction and venue.
3) Responsibility. Each Party shall be responsible for its negligent acts or omissions and the negligent acts or
omission of its employees, officers, or director's, to the extent allowed by law.
4) Limitation of Damages. In no event shall either party be liable to the other party for any claims by the other
party for indirect, incidental, consequential, special, punitive, or exemplary damages, including lost profits, arising
or alleged to arise from this Agreement, its breach, or the transactions contemplated herein, however caused,
under any theory of liability.
5) Copyrights. Subrecipient _ grants / X shall grant (check one) to UW an irrevocable, royalty -free, non-
transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform
publicly any copyrights or copyrighted material (including any computer software and its documentation and/or
databases) first developed and delivered under this Subaward Agreement solely for the purpose of and only to
the extent required to meet UW's obligations under UW's Prime Award.
6) Data Rights. Subrecipient grants to UW the right to use data created by Subrecipient in the performance of
this Subaward Agreement solely for the purpose of and only to the extent required to meet UW's obligations
under UW's Prime Award.
7) Automatic Carry Forward: [) Yes f X 1 No
(If No, Carry Forward requests must be sent to UW's Administrative and Principal Investigator contact, as shown
in Attachment 3A).
8) Human Subjects Protections: Subrecipient will comply with all applicable regulations, laws, and policies
regarding human subjects protections. Subrecipient shall provide UW copies of IRB approval letter. No
obligations may be made against Federal funds for any research involving human subjects prior to IRB approval.
UW Research DOMESTIC Subaward Agreement Page 1
Version 1 9 29 2016
Attachment 3A Subaward Number:
Research Subaward Agreement � UWSC12491
Prime Recipient Contacts
Prime Recipient Entity
Name: University of Washington, Office of Sponsored Programs
Address: 4333 Brooklyn Ave NE
Box 359472
City: Seattle State: WA
Prime Recipient's Administrative Contact
Name: Josy S. Combs, Subaward Administrator
Address: Office of Sponsored Programs
4333 Brooklyn Ave NE
Box 359472
City: Seattle State: WA
Telephone: (206) 543-7052 Fax: (206) 685-1732
E-mail: combsj3@uw.edu
Prime Recipient's Principal Investigator
Name: Sara Glick
Address: UW School of Medicine
Department of Medicine, Allergy and Infectious Diseases
Box 359777
City: Seattle State: WA
Telephone: Fax:
E-mail: snglick@uw.edu
Prime Recipient's Financial Contact
Name: Kristen Emanuel
Address: UW School of Medicine
Department of Medicine, Allergy and Infectious Diseases
Box 358220
City: Seattle
Telephone: (206) 616-2019
E-mail: kemanuel@uw.edu
Prime Recipient's Authorized Official
Name: Director
Address: Office of Sponsored Programs
4333 Brooklyn Ave NE
Box 359472
Fax:
State: WA
zip Code: 98195-9472
zip Code: 98195-9472
Zip Code: 98195-9777
Zip Code: 98195-8220
City: Seattle State: WA zip Code: 98195-9472
Telephone: (206) 543-4043 Fax: (206) 685-1732
E-mail: ospsubs@uw.edu
Attachment 3B Subaward Number:
Research Subaward Agreement UWSC12491
Subrecipient Contacts
Subrecipient Place of Performance Pf
Name: `I 1�( S��vl ii p 6r`I'K
Address: 0767 W N641';M S � �7'l, `0r -
city: L1S 4State: �(,� /4 ` qq
J ZipCode+4: lG'-
n;� (Look up) Q�,/
E?N No.: OI --WO j qCI Institution Type: LWIL( j E)UeMA M C1 Mrw
Is Subrecipient currently registered in SAM.gov? N Yes � No `J
DUNS No.: o ( pZ(72'-.>{? Parent DUNS No.:
Subrecipient Administrative Contact
Name: r u� � lr' i•�) G({7� ��
Address: l
50`7 N Oco"Vt S41 S �� Z
City: VU-VLS �j{,(,
Telephone: 15cl-cA-__71515
Email ��"e. Oc (Ctc_C.1 L, Cj> �"`1)�(S WGA( ' us
Subrecipient Principal Investigator (PI)
Name:
Address:
c, D7
w X0jjM
City:U0 " 1w
Telephone: — (eL— �S S
E-mail: G%�Cs�� • ��E�- ��+�, F�l�1 S• W11 - LAS
Subrecipient Financial Contact
Name:Tivkk R171wG1 C �p
Address: Gb / X) NCLV�Wh 54- S [1)2 -
City: 'E1 (wSw_t 1
Telephone:
Congressional District:
State:w, A
Fax: 1;0i--
State: 1W 24
Fax:
State: Lu A `
Fax: 7bq +I(PZ_—
E-mail: `t VNcl- Con V` \s CZ' k-�` 1 /+ci5C1 - LlS
Subrecipient Authorized Official,,
Name: Tr c>" l..Ecm ` to t
Address: 90-7 MMaV uw-, 7r) SIC- 02
Congressional District:
Zip Code:
Zip Code +4:I 4:198Q2&.-
-2-Vy G
Zip Code: cM Lt. —
284le
City: eu.oC-GL. State: W� C ) Zip Code: W1
Telephone: 7�Lf` � tf22- `75- Fax; sbel-q&2-7781
E-mail: -61 -Ato tztw 10 (-,o W • fc�s, wa • lis
Attachment 3B Page 2
Subaward
Research Subaward Agreement
Highest Compensated Officers UWSC12491
Number:
Subrecipient
Name: S CU -1,0 V, IbVC, l
FoaTux
Pk:
Is Subrecipient exempt from reporting compensation? Yes ®
?? No
Subrecipient is not exempt from reporting executive compensation if:
1) The Subrecipient received 80 percent or more of its annual gross revenues in Federal awards in the preceding fiscal year; and
2) The Subrecipient received $25,000,000 or more in annual gross revenues from Federal awards; and
3) The public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a)
or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§§78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal
Revenue Code of 1986.
Highest Compensated Officers
Officer 1 Name ( G� 1
Officer 1 Compensation G� 3� --76 1
Officer 2 Name I ,Q ; ac V– c
Officer 2 Compensation FT-7� 1 I _M
Officer Name
Officer 3 Compensation 14-CP4,fl V5-7
Officer 4 Name Cz
x
Officer 4 Compensation %&)Lf) Z,
Officer 5 Name A,i
Officer 5 Compensation `$ 13� ( / 5 Z
Attachment 4
Research Subaward Agreement
Reporting Requirements
Prime Recipient will check all that apply that the Subrecipient will agree to.
® A Final technical/progress report will be submitted to the Prime Recipient's Principal Investigator
identified in Attachment 3 within 60 days after the end of the period of performance.
❑ Monthly technical/progress reports will be submitted to the Prime Recipient's Financial Contact
identified in Attachment 3, within 15 days of the end of the month.
Quarterly technical/progress reports will be submitted within thirty (30) days after the end of each project quarter
to the Prime Recipient's Administrative Contact identified in Attachment 3.
® Technical/progress reports on the project as may be required by Prime Recipient's Principal Investiqator
in order that Prime Recipient may be able to satisfy its reporting obligations to the Awarding Agency.
Annual technical /progress reports will be submitted within 90 days prior to the end of each project
period to the Prime Recipient's Principal Investiqator identified in Attachment 3. Such report shall also
include a detailed budget for the next budget period, updated Other Support for key personnel, certification of
appropriate education in the conduct of human subject research of any new key personnel, and annual IRB or
IACUC approval, if applicable.
® In accordance with 37 CFR 401.14, Subrecipient agrees to notify UW's Principal Investiqator identified in
Attachment 3A within 30 days after Subrecipient's inventor discloses invention(s) in writing to
Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report
using Awarding Agency specific forms to the UW's Principal Investiqator identified in Attachment 3A within
60 days of the end of the period of performance so that it may be included with the UW's final
invention report to the Awarding Agency. A negative report =is= is not required.
® A Certification of Completion, in accordance with 2 CFR 200.201(b)(3), will be submitted within 90 days
after the end of the project period to the Prime Reecipient's Administrative Contact identified in
Attachment 3 (for Fixed Price subawards only.)
❑ Property Inventory Report; frequency, type, and submission instructions listed here and only to be used
when required by UW Award
Other Special Reporting Requirements
ATTACHMENT 5
Research Subaward Agreement
STATEMENT OF WORK
If award is FFATA eligible and SOW exceeds 4000 characters, include a Subrecipient Federal Award Project Description
Components 2a*
1. Participate in weekly videoconference calls with University of Washington (UW) and other
partners to receive guidance and training on Project NEXUS activities.
a. Provide ongoing feedback to UW on protocol implementation issues or concerns.
2. Recruit and enroll 150 (up to 175) people who inject drugs and their drug using peers to
participate in Project NEXUS activities at the Never Share Syringe Exchange at KCPHD.
a. Appropriately staff Project NEXUS at your enrollment site.
b. Closely adhere to Project NEXUS guidance documents for data collection, participant
and staff safety precautions.
c. Closely adhere to Project NEXUS timelines and communicate any risks to the timeline.
*All work to be completed in collaboration with the UW and other project partners.
UW Research ATT 5 Scope SEP 2016
ATTACHMENT 5
Cost Reimbursement Research Subaward Agreement
Budget
Direct Costs $76,006
Indirect Cost Rate (IDC) of 42% ❑ TDC ❑ MTDC ® Other Indirect Costs $19,930
De Minimis rate applied? ❑ (Check if YES) TOTAL COSTS $95,936
Salaries $52,447
Employee Benefits $7,039
Equipment $0
Travel $0
Supplies $6,070
Other Direct Costs $10,450
Total Direct Costs
Indirect Cost 38% of Salaries & Wages*
$76,006
$19,930
GRAND TOTAL $95,936
*Indirect costs at 38% in accordance with Subrecipient negotiated rates approved 12/31/2019.
UW Research Budget Template SEP 2016